Endurance Bio

Endurance Bio is an early-stage biotech targeting the fundamental biology of aging and disease by enhancing mitochondrial and lysosomal function. The company's pipeline is led by T-168, a candidate ready for Phase 2 trials in ALS, Parkinson's, and Alzheimer's disease, with notable inclusion in an externally funded Parkinson's trial in Norway. With a second asset, T-621, in IND-enabling studies, the company is positioning itself in the high-need, high-value space of neurodegenerative and age-related diseases, backed by a lean team and key scientific advisors.

Discovery and development of first-in-class small molecules designed to rejuvenate cellular mitochondria and lysosomes, reducing oxidative stress and inflammation while enhancing autophagy.

Endurance Bio competes in the crowded neurodegenerative space against large pharma and biotechs, but differentiates by targeting mitochondrial/lysosomal function. It also faces emerging competition from other geroscience companies targeting hallmarks of aging. Its specific molecular mechanisms and early partnership validation are key differentiators.